ATYR
aTYR PHARMA INC
$0.4700
-8.38%
$46.1M
No data for this timeframe.
Vol
Market Cap$46.1M
Cap SizeNano Cap
Analyst ConsensusBuy (60%)
Inst. Holders7 funds
Inst. Value$17.2M
Inst. Activity2 buys / 1 sells
Insider Activity1B / 3S
Insider Net $$43.4K
SEC Reports6
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001339970·Prev Close $0.5130
Recent Activity
Jun 1, 2026
SEC
aTyr Pharma filed an 8-K with an investor presentation detailing plans for a new Phase 3 study (C-006) of efzofitimod in
8-K — Impact 4/10
May 27, 2026
Insider
SCHIMMEL PAUL bought 100,000 shares
Director @ $0.4963 ($49.6K)
May 26, 2026
short_volume
Short Volume: ATYR — 58.2% short (0.8M / 1.4M)
Short: 798,325 | Exempt: 0 | TRF Vol: 1,371,937 | Short Ratio: 58.2% | Off-exchange volume (dark poo
May 15, 2026
SEC
aTyr Pharma reported Q1 2026 net loss of $10.8M ($0.11/share), narrower than the prior year, and ended the quarter with
8-K — Impact 5/10
May 15, 2026
SEC
aTyr Pharma reported Q1 2026 EPS of -$0.14, a 3.9% beat vs consensus of -$0.15, on no revenue. The company announced pla
PRESS-RELEASE — Impact 5/10
May 11, 2026
Insider
SCHIMMEL PAUL sold 50,000 shares
Director @ $0.00 ($0.00)
May 11, 2026
Insider
Zaknoen Sara sold 50,000 shares
Director @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — ADD
1,403,009 shares ($1.1M)
Price Targets
$2.86
+507.9% upside
Strong Buy
Current $0.4700
Low $1.00
Median $3.00
High $7.00
7 analysts
$1.00
$7.00
Analyst Ratings
3Strong Buy
6Buy
6Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 20, 2026 | Freedom Broker | UPGRADE | Hold → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.12 ▲ +21.1% | $-0.14 — $-0.10 | 46% YoY | 6 |
| Next Q | $-0.13 ▲ +14.4% | $-0.16 — $-0.10 | 49% YoY | 6 |
| Current FY | $-0.52 ▲ +13.1% | $-0.63 — $-0.43 | 35% YoY | 6 |
| Next FY | $-0.58 ▼ -39.9% | $-0.86 — $-0.28 | -11% YoY | 8 |
Latest Reports
NEUTRAL
8-K
4/10
aTyr Pharma filed an 8-K with an investor presentation detailing plans for a new Phase 3 study (C-006) of efzofitimod in
Jun 1, 2026
BULLISH
8-K
5/10
aTyr Pharma reported Q1 2026 net loss of $10.8M ($0.11/share), narrower than the prior year, and ended the quarter with
May 15, 2026
MIXED
Press
6/10
aTyr Pharma reported full-year 2025 financial results and provided a clinical update, including that its Phase 3 EFZO-FI
Mar 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $11.5M | — |
| VANGUARD GROUP INC | $3.9M | — |
| MORGAN STANLEY | $1.1M | ADD |
| TWO SIGMA INVESTMENTS, LP | $355.9K | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $173.7K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 27, 2026 | SCHIMMEL PAUL | BUY | $49.6K |
| May 11, 2026 | SCHIMMEL PAUL | A | $0.00 |
| May 11, 2026 | Zaknoen Sara | A | $0.00 |
| May 11, 2026 | Lucas Svetlana | A | $0.00 |
| May 11, 2026 | Gross Jane | A | $0.00 |
7 institutional holders with $17.2M total value (21,982,502 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, MORGAN. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 14,697,995 | $11.5M | 66.9% | — |
| 2 | VANGUARD GROUP INC | 4,961,871 | $3.9M | 22.6% | — |
| 3 | MORGAN STANLEY | 1,403,009 | $1.1M | 6.4% | ADD +97.5% |
| 4 | TWO SIGMA INVESTMENTS, LP | 454,443 | $355.9K | 2.1% | DOUBLED +115.4% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 221,767 | $173.7K | 1.0% | DOUBLED +547.8% |
| 6 | BANK OF AMERICA CORP /DE/ | 126,700 | $99.2K | 0.6% | TRIM -28.7% |
| 7 | WELLS FARGO & COMPANY/MN | 116,717 | $91.4K | 0.5% | TRIM -60.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 710,341 | 1,403,009 | +97.5% | $1.1M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 211,000 | 454,443 | +115.4% | $355.9K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 177,671 | 126,700 | -28.7% | $99.2K | 2025-Q4 |
| UBS Group AG | DOUBLED | 1,745,717 | 4,505,955 | +158.1% | $3.2M | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 259,966 | 710,341 | +173.2% | $512.4K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 31,328 | 211,000 | +573.5% | $152.2K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 42,346 | 177,671 | +319.6% | $128.1K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 277,388 | 111,059 | -60.0% | $80.1K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 518,355 | 0 | -100.0% | $0.00 | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 168,219 | 277,388 | +64.9% | $1.4M | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 39,911 | 258,551 | +547.8% | $1.3M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 288,311 | 42,346 | -85.3% | $214.7K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | ADD | 22,239 | 31,328 | +40.9% | $158.8K | 2025-Q2 |
| UBS Group AG | DOUBLED | 229,576 | 1,637,186 | +613.1% | $4.9M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 56,261 | 395,407 | +602.8% | $1.2M | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 41,213 | 262,679 | +537.4% | $793.3K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 105,769 | 168,219 | +59.0% | $508.0K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,149,175 | 574,455 | -50.0% | $2.1M | 2024-Q4 |
| UBS Group AG | NEW | — | 229,576 | — | $831.1K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 2,500 | 105,769 | +4130.8% | $382.9K | 2024-Q4 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 985,207 | 56,261 | -94.3% | $203.7K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 1 | 41,213 | +4121200.0% | $149.2K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 26,689 | 39,689 | +48.7% | $143.7K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 26,689 | — | $47.0K | 2024-Q3 |
9 unique insiders with 4 transactions. Net insider value: $43.4K ($49.6K bought, $6.3K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 27, 2026 | SCHIMMEL PAUL | Director | BUY | 100,000 | $0.4963 | $49.6K |
| May 11, 2026 | SCHIMMEL PAUL | Director | A | 50,000 | $0.00 | $0.00 |
| May 11, 2026 | Zaknoen Sara | Director | A | 50,000 | $0.00 | $0.00 |
| May 11, 2026 | Lucas Svetlana | Director | A | 50,000 | $0.00 | $0.00 |
| May 11, 2026 | Gross Jane A | Director | A | 50,000 | $0.00 | $0.00 |
| May 11, 2026 | BENEVICH ERIC | Director | A | 50,000 | $0.00 | $0.00 |
| May 11, 2026 | Coughlin Timothy | Director | A | 50,000 | $0.00 | $0.00 |
| Feb 4, 2026 | Shukla Sanjay | President and CEO | SELL | 3,745 | $0.9760 | $3.7K |
| Feb 4, 2026 | DENYES NANCY | General Counsel | SELL | 1,118 | $0.9761 | $1.1K |
| Feb 4, 2026 | Broadfoot Jill Marie | Chief Financial Officer | SELL | 1,558 | $0.9760 | $1.5K |
| Feb 3, 2026 | Shukla Sanjay | President and CEO | M | 10,375 | $0.00 | $0.00 |
| Feb 3, 2026 | Shukla Sanjay | President and CEO | M | 10,375 | $0.00 | $0.00 |
| Feb 3, 2026 | DENYES NANCY | General Counsel | M | 2,687 | $0.00 | $0.00 |
| Feb 3, 2026 | DENYES NANCY | General Counsel | M | 2,687 | $0.00 | $0.00 |
| Feb 3, 2026 | Broadfoot Jill Marie | Chief Financial Officer | M | 3,750 | $0.00 | $0.00 |
| Feb 3, 2026 | Broadfoot Jill Marie | Chief Financial Officer | M | 3,750 | $0.00 | $0.00 |
6 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 2 mixed, 3 neutral. Avg impact: 4.7/10.
NEUTRAL
8-K
4/10
aTyr Pharma filed an 8-K with an investor presentation detailing plans for a new Phase 3 study (C-00
Jun 1, 2026
BULLISH
8-K
5/10
aTyr Pharma reported Q1 2026 net loss of $10.8M ($0.11/share), narrower than the prior year, and end
May 15, 2026
NEUTRAL
PRESS-RELEASE
5/10
aTyr Pharma reported Q1 2026 EPS of -$0.14, a 3.9% beat vs consensus of -$0.15, on no revenue. The c
May 15, 2026
MIXED
8-K
6/10
aTyr Pharma announced it will proceed with a new Phase 3 trial (C-006) for efzofitimod in pulmonary
May 11, 2026
NEUTRAL
DEFA14A
2/10
Analysis based on filing metadata only — document content was unavailable
Mar 26, 2026
MIXED
8-K
6/10
aTyr Pharma reported full-year 2025 financial results and provided a corporate update, including the
Mar 5, 2026
Current analyst consensus: Buy (60% buy). Based on 15 analysts: 3 strong buy, 6 buy, 6 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$2.86 mean target
+507.9% upside
Strong Buy (3.00)
$1.00 Low
$7.00 High
| Metric | Value |
|---|---|
| Current Price | $0.4700 |
| Target Low | $1.00 |
| Target Mean | $2.86 |
| Target Median | $3.00 |
| Target High | $7.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.12 | $-0.14 | $-0.10 | 46.2% | +21.1% | 4↑ 0↓ | $0.0B | 0.0% | 6 |
| Next Q 2026-09-30 |
$-0.13 | $-0.16 | $-0.10 | 48.7% | +14.4% | 2↑ 0↓ | $0.0B | -100.0% | 6 |
| Current FY 2026-12-31 |
$-0.52 | $-0.63 | $-0.43 | 34.6% | +13.1% | 4↑ 0↓ | $0.0B | -100.0% | 6 |
| Next FY 2027-12-31 |
$-0.58 | $-0.86 | $-0.28 | -11.3% | -39.9% | 2↑ 3↓ | $0.0B | 0.0% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.118 | |
| 7d ago | $-0.140 | +0.022 |
| 30d ago | $-0.150 | +0.032 |
| 60d ago | $-0.150 | +0.032 |
| 90d ago | $-0.132 | +0.014 |
1 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 20, 2026 | Freedom Broker | UPGRADE | Hold | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 6 | 6 | 0 | 0 | 60% | |
| May 1, 2026 | 3 | 5 | 8 | 0 | 0 | 50% | |
| Apr 1, 2026 | 3 | 5 | 8 | 0 | 0 | 50% | |
| Mar 1, 2026 | 3 | 6 | 8 | 0 | 0 | 53% | |
| Feb 1, 2026 | 3 | 5 | 8 | 0 | 0 | 50% | |
| Jan 1, 2026 | 3 | 5 | 8 | 0 | 0 | 50% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
Clinical Trial
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
Phase Phase 3 — COMPLETED
May 26, 2026
short_volume
Short Volume: ATYR — 58.2% short (0.8M / 1.4M)
Short: 798,325 | Exempt: 0 | TRF Vol: 1,371,937 | Short Ratio: 58.2% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: ATYR — 66.0% short (1.0M / 1.6M)
Short: 1,048,789 | Exempt: 0 | TRF Vol: 1,590,239 | Short Ratio: 66.0% | Off-exchange volume (dark pool + OTC)
May 15, 2026
earnings
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
May 13, 2026
earnings_calendar
ATYR Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
other
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
May 5, 2026
earnings_calendar
ATYR Q1 2026 Earnings Scheduled — 2026-05-05
Apr 29, 2026
short_volume
Short Volume: ATYR — 60.8% short (0.3M / 0.6M)
Short: 339,788 | Exempt: 0 | TRF Vol: 558,633 | Short Ratio: 60.8% | Off-exchange volume (dark pool + OTC)
Apr 9, 2026
short_volume
Short Volume: ATYR — 78.0% short (0.5M / 0.6M)
Short: 466,730 | Exempt: 0 | TRF Vol: 598,432 | Short Ratio: 78.0% | Off-exchange volume (dark pool + OTC)
Apr 7, 2026
short_volume
Short Volume: ATYR — 63.7% short (0.3M / 0.5M)
Short: 335,615 | Exempt: 3,270 | TRF Vol: 526,571 | Short Ratio: 63.7% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
short_volume
Short Volume: ATYR — 67.0% short (0.6M / 0.9M)
Short: 613,369 | Exempt: 0 | TRF Vol: 914,881 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)
Mar 27, 2026
short_volume
Short Volume: ATYR — 75.8% short (0.6M / 0.8M)
Short: 571,766 | Exempt: 0 | TRF Vol: 753,940 | Short Ratio: 75.8% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
short_volume
Short Volume: ATYR — 55.2% short (0.3M / 0.6M)
Short: 314,581 | Exempt: 0 | TRF Vol: 569,886 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
Mar 12, 2026
earnings_calendar
ATYR Q4 2025 Earnings After Market Close — 2026-03-12
Mar 11, 2026
earnings_calendar
ATYR Q4 2025 Earnings After Market Close — 2026-03-11
Mar 5, 2026
earnings
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update